Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies

Several T cell-boosting anticancer therapies (including anti-CD19 CAR-T cells and bi-specific T cell engagers, BiTEs) have been approved by the FDA for specific clinical indications. Their potency has been demonstrated in various clinical trials, but some life-threatening complications such as neuro...

Full description

Saved in:
Bibliographic Details
Published in:Trends in immunology 2019-04, Vol.40 (4), p.274-278
Main Authors: Zheng, Ping-Pin, Kros, Johan M., Wang, Guanyu
Format: Article
Language:English
Subjects:
BiTEs
Brain research
Cancer therapies
CAR-T
CD19 antigen
Clinical trials
CNS damage
Complications
Cytokines
Cytotoxicity
Design
encephalopathy
Immune system
Immunotherapy
Leukemia
Lymphocytes
Lymphocytes T
Medical research
Metabolites
Neurotoxicity
Patients
Pediatrics
T cell-boosting therapies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several T cell-boosting anticancer therapies (including anti-CD19 CAR-T cells and bi-specific T cell engagers, BiTEs) have been approved by the FDA for specific clinical indications. Their potency has been demonstrated in various clinical trials, but some life-threatening complications such as neurotoxicity remain poorly understood. Thus, by conducting multifaceted investigations, a better understanding of T cell immunotherapy-associated neurotoxicity to bridge the gap between basic research and clinical practice is urgently needed.
ISSN:1471-4906
1471-4981
DOI:10.1016/j.it.2019.02.005